Health
ACROFAN – ACROFAN USA
Study published in Nature shows J&J’s investigational SARS-CoV-2 vaccine elicits a strong immune response that protects against subsequent infection First-in-human Phase 1/2a clinical trial now underway in United States and Belgium; Phase 3 clinical trial e…
Study published in Nature shows J&J’s investigational SARS-CoV-2 vaccine elicits a strong immune response that protects against subsequent infection
First-in-human Phase 1/2a clinical trial now underway in United States and Belgium; Phase 3 clinical trial expected to commence in September
NEW BRUNSWICK, New Jersey, July 30, 2020 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the v…
-
Noosa News13 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News21 hours agoDifficult to diagnose and potentially deadly — this lesser-known disease is becoming more common
-
General24 hours agoUS authorities to set targets to lower medicine prices
-
Noosa News12 hours agoDefence investigation finds Taipan pilot’s actions possibly prevented further fatalities in crash